Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
9.9
5.1
Journals
Cells
Special Issues
Nitric Oxide in Cancer Therapy: Facts and Opportunities
share announcement

Nitric Oxide in Cancer Therapy: Facts and Opportunities

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cellular Pathology".

Deadline for manuscript submissions: closed (31 July 2021) | Viewed by 17728

Special Issue Editor

Dr. Stéphanie Plenchette

E-Mail Website
Guest Editor
1. Laboratoire d'Immunologie et Immunothérapie des Cancers, EPHE, PSL Research University, 75000 Paris, France
2. LIIC, EA7269, université de Bourgogne Franche-Comté, 21000 Dijon, France
Interests: Nitric oxide; cancer; S-nitrosylation; signaling pathways; tumor microenvironment; inflammation; immune cells; chemotherapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Our growing understanding of the role of nitric oxide (NO) in cancer biology eventually uncovered its therapeutic potential. Harnessing the pleiotropic anticancer properties of NO represents a promising therapeutic opportunity. For various types of tumor cells, a meaningful role for NO as a sensitizer, by augmenting the effectiveness and/or by overcoming resistance to conventional therapies, has emerged from preclinical and/or clinical research. Although some combinatory strategies (NO-releasing drugs/conventional therapies) demonstrated some clinical benefit, further insights are needed to reach successful NO-based therapy regimen for cancer treatment.

This special issue of Cells aims to gather recent findings from basic to translational research in the field of NO to contribute to devise possible new therapeutic strategies for cancer treatment. It will welcome original research articles and review articles covering all relevant aspects of the antitumor spectrum of NO with an emphasis on potential combinatorial therapeutic strategies:  NO-releasing drugs combined with conventional therapies (chemotherapy, radiotherapy and immunotherapy) or novel anticancer molecules. New insights in the molecular mechanisms of NO events and cellular responses or changes within the tumor microenvironment are of particular interest.  The scope of this special issue will address, but is not limited to, cellular signaling involved in tumor cell death and immune responses under the control of NO. The impact of NO on protein function (NO-mediated protein post-translation modifications such as S-nitrosylation, metal-nitrosylation or nitration), technical advances to improve NO delivery to targeted sites and antitumor efficacy are also key topics. 

I look forward to your contributions.

Dr. Stéphanie Plenchette
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Nitric oxide
  • Cancer
  • Combined therapy
  • Sensitization
  • Tumor microenvironment
  • Intracellular signaling
  • Post-translational modifications
  • Cell death
  • Immune cells

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

22 pages, 2895 KiB  
Review
Macrophage Reprogramming and Cancer Therapeutics: Role of iNOS-Derived NO
by Khosrow Kashfi, Jasmine Kannikal and Niharika Nath
Cells 2021, 10(11), 3194; https://doi.org/10.3390/cells10113194 - 16 Nov 2021
Cited by 98 | Viewed by 11442
Abstract
Nitric oxide and its production by iNOS is an established mechanism critical to tumor promotion or suppression. Macrophages have important roles in immunity, development, and progression of cancer and have a controversial role in pro- and antitumoral effects. The tumor microenvironment consists of [...] Read more.
Nitric oxide and its production by iNOS is an established mechanism critical to tumor promotion or suppression. Macrophages have important roles in immunity, development, and progression of cancer and have a controversial role in pro- and antitumoral effects. The tumor microenvironment consists of tumor-associated macrophages (TAM), among other cell types that influence the fate of the growing tumor. Depending on the microenvironment and various cues, macrophages polarize into a continuum represented by the M1-like pro-inflammatory phenotype or the anti-inflammatory M2-like phenotype; these two are predominant, while there are subsets and intermediates. Manipulating their plasticity through programming or reprogramming of M2-like to M1-like phenotypes presents the opportunity to maximize tumoricidal defenses. The dual role of iNOS-derived NO also influences TAM activity by repolarization to tumoricidal M1-type phenotype. Regulatory pathways and immunomodulation achieve this through miRNA that may inhibit the immunosuppressive tumor microenvironment. This review summarizes the classical physiology of macrophages and polarization, iNOS activities, and evidence towards TAM reprogramming with current information in glioblastoma and melanoma models, and the immunomodulatory and therapeutic options using iNOS or NO-dependent strategies. Full article
(This article belongs to the Special Issue Nitric Oxide in Cancer Therapy: Facts and Opportunities)
►▼ Show Figures

Figure 1

22 pages, 2376 KiB  
Review
Regulation of T Cells in Cancer by Nitric Oxide
by Inesa Navasardyan and Benjamin Bonavida
Cells 2021, 10(10), 2655; https://doi.org/10.3390/cells10102655 - 5 Oct 2021
Cited by 30 | Viewed by 5573
Abstract
The T cell-mediated immune response is primarily involved in the fight against infectious diseases and cancer and its underlying mechanisms are complex. The anti-tumor T cell response is regulated by various T cell subsets and other cells and tissues in the tumor microenvironment [...] Read more.
The T cell-mediated immune response is primarily involved in the fight against infectious diseases and cancer and its underlying mechanisms are complex. The anti-tumor T cell response is regulated by various T cell subsets and other cells and tissues in the tumor microenvironment (TME). Various mechanisms are involved in the regulation of these various effector cells. One mechanism is the iNOS/.NO that has been reported to be intimately involved in the regulation and differentiation of the various cells that regulate the anti-tumor CD8 T cells. Both endogenous and exogenous .NO are implicated in this regulation. Importantly, the exposure of T cells to .NO had different effects on the immune response, depending on the .NO concentration and time of exposure. For instance, iNOS in T cells regulates activation-induced cell death and inhibits Treg induction. Effector CD8 T cells exposed to .NO result in the upregulation of death receptors and enhance their anti-tumor cytotoxic activity. .NO-Tregs suppress CD4 Th17 cells and their differentiation. Myeloid-derived suppressor cells (MDSCs) expressing iNOS inhibit T cell functions via .NO and inhibit anti-tumor CD8 T cells. Therefore, both .NO donors and .NO inhibitors are potential therapeutics tailored to specific target cells that regulate the T cell effector anti-tumor response. Full article
(This article belongs to the Special Issue Nitric Oxide in Cancer Therapy: Facts and Opportunities)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop